Company intelligence / Profile preview

Freya Pharma Solutions

Amsterdam, Netherlandsfreyapharmasolutions.com ↗

Ownership: Private
Development stage: Other

Overview

Lead program "Lybrido" has shown statistically and clinically relevant improvements in sexual experience in women with FSIAD/HSDD and is advancing through Phase 3 clinical trials[1][5].

Therapeutic areas: Women's Health
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Lybridos

Partnerships

CR2O BV (CRO partner leading Phase 3 trial preparation and execution)[1]

Beyond the preview

Go deeper on Freya Pharma Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freya Pharma Solutions.